Drug Development for Botulism

National Institute Of Allergy And Infectious Diseases

Investigators

Abstract

This Interagency Agreement provides for the production and characterization of Clostridium botulinum toxins and for the use of these toxins as immunogens to derive monoclonal antibodies.